AI Target Discovery
Leveraging reverse immunology and generative AI to discover novel therapeutic targets.
Executive Summary
Absci's AI Target Discovery platform utilizes a pioneering reverse immunology approach combined with generative AI to identify novel antibody/target pairs. This technology focuses on discovering new therapeutic targets by analyzing the immune responses of "super immune responders." The platform integrates high-throughput wet lab data with advanced AI models to accelerate the discovery process. The core methodology involves understanding natural immunology to uncover previously unknown drug targets. This allows for the identification of differentiated biology, leading to the development of breakthrough biologics. Beyond target discovery, Absci's platform also supports lead optimization and de novo antibody design, aiming to improve antibody function and drug-like properties more rapidly.
Use Cases
- Identifying novel therapeutic targets for various diseases.
- Discovering new antibody/target pairs from super immune responders.
- Accelerating the early-stage drug discovery pipeline for biologics.
- Uncovering differentiated biology for breakthrough drug development.
Features
Intelligence
- Novel Target Identification: Identifies previously unknown therapeutic targets by analyzing natural immune responses.
- Antibody/Target Pair Discovery: Uncovers new pairs of antibodies and their corresponding targets from super immune responders.
- Generative AI for Biologics: Utilizes generative AI to predict and design novel biologics with improved properties.
Technical Specifications
- Architecture
- Integrated AI drug creation platform with wet lab and AI iterative cycles
- Deployment
- SaaS
AI/ML Stack
- Generative AI
- Machine Learning
- Reverse Immunology
Pricing
- Model
- Partnership-based
- Starting Price
- Contact sales
- Target Customer
- Enterprise
- Contract Type
- Partnership-based
- Free Trial
- No
About Absci
Absci is a clinical-stage biopharmaceutical company that leverages its Integrated Drug Creation™ platform, combining generative AI with synthetic biology to design and advance novel biologic therapeutics faster. They aim to create better biologics for patients by unifying drug discovery and cell line development into one simultaneous process.
Alternatives to AI Target Discovery
- AlphaFold 3 by Isomorphic Labs — Predicting the structures and interactions of all of life's molecules with unprecedented accuracy.
- AtomNet by Atomwise — Deep-learning virtual screening to find novel small-molecule hits faster
- BenevolentAI Platform by BenevolentAI — AI-driven drug discovery: accelerating science, transforming medicine.
- Chemistry42 by Insilico Medicine — A generative AI platform for small molecule drug discovery, streamlining hit identification to lead optimization.
- ChemML Discovery Platform by Insitro — Accelerating drug discovery through chemistry machine learning and strategic collaborations.
- Cortellis by Clarivate — Equip your R&D ecosystem with intelligence to make confident, speedy decisions across drug and device development.
- Cyprotex by Evotec — Predictive ADME-Tox solutions for enhanced drug safety and success.
- DORA by Insilico Medicine — AI-driven tool to streamline academic paper drafting and accelerate drug discovery research.